Registration Dossier

Data platform availability banner - registered substances factsheets

Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.

The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.

Diss Factsheets

Toxicological information

Developmental toxicity / teratogenicity

Currently viewing:

Administrative data

Endpoint:
developmental toxicity
Type of information:
read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Study period:
May 29, 1995 to June 29, 1995.
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Some deviations such as the treatment period (from GD6 to GD15 instead of GD5 to GD15 mentioned in OECD guideline 414).
Justification for type of information:
The justification for read across is provided as an attachment in IUCLID Section 13.
Cross-referenceopen allclose all
Reason / purpose for cross-reference:
read-across: supporting information
Reference
Endpoint:
developmental toxicity
Type of information:
read-across from supporting substance (structural analogue or surrogate)
Adequacy of study:
key study
Study period:
May 29, 1995 to June 29, 1995.
Reliability:
2 (reliable with restrictions)
Rationale for reliability incl. deficiencies:
other: Some deviations such as the treatment period (from GD6 to GD15 instead of GD5 to GD15 mentioned in OECD guideline 414).
Justification for type of information:
The justification for read across is provided as an attachment in IUCLID Section 13.
Reason / purpose for cross-reference:
read-across source
Reason / purpose for cross-reference:
reference to other study
Species:
rat
Details on maternal toxic effects:
Maternal toxic effects:no effects

Details on maternal toxic effects:
No maternal toxic effects.
Dose descriptor:
NOAEL
Effect level:
> 1 000 mg/kg bw/day (nominal)
Basis for effect level:
other: maternal toxicity
Details on embryotoxic / teratogenic effects:
Embryotoxic / teratogenic effects:yes

Details on embryotoxic / teratogenic effects:
There were statistically significant differences in individual skeletal variations, but were limited to an increase in the incidence of rudimentary lumbar ribs in the 400 mg/kg dose group (14.2%) compared with controls (4.2%) on a per fetus basis. This increased incidence was within the historical control range of this laboratory (3.7-28.8), greater than that observed at higher doses, and thus, not considered biologically important.
The statistically significant increases in the total fetuses with skeletal variations in the 400 mg/kg dose groups were directly driven by the increased incidence of rib variations and thus, were similarly considered as biologically unimportant (within HC range).
Dose descriptor:
NOAEL
Effect level:
> 1 000 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: Developmental Toxicity
Abnormalities:
no effects observed
Developmental effects observed:
no

No remarks

Conclusions:
In conclusion, overt signs of maternal toxicity were not apparent at any dose tested, as indicated by the absence of adverse clinical or postmortem findings or effects on body weight, food consumption, and/or uterine implantation data. Similarly, there were no treatment-related adverse effects on fetal development or growth observed at any dose level tested. Accordingly, the maternal and developmental NOAELs (No Observable Adverse Effect Level) were established at 1000 mg/kg (the limit dose) under the conditions of this study.
Executive summary:

This data is being read across from the source study that tested Hydrocarbons, C16-C20, n-alkanes, isoalkanes, cyclics, ≤2% aromatics based on analogue read across.

The test material was administered by oral gavage to three groups of Crl:CDBR female rats at doses of 400, 800, and 1000 mg/kg/day. A fourth group (Group 1) served as a control and received the carrier (corn oil) only. Mated females were dosed once daily from Gestation Day (GD) 6 through GD 15. Dosing volumes were 5 mL/kg for all groups and based on the animals' most recent body weights.

There was no evidence of overt systemic maternal toxicity at any dose level tested. overt signs of maternal toxicity were not apparent at any dose tested, as indicated by the absence of adverse clinical or postmortem findings or effects on body weight, food consumption, and/or uterine implantation data.

Similarly, there were no treatment-related adverse effects on fetal development or growth observed at any dose level tested. There was a statistically significant increase in the incidence of rudimentary ribs in the low dose (400 mg/kg/day) group, but not at the higher doses, compared with controls, which resulted in an increased incidence of total fetuses with skeletal variations in the 400 mg/kg/day group. However, all these incidences were within the historical control range of this laboratory. Therefore, this common finding in fetal rats was not considered biologically important.

Accordingly, the maternal and developmental NOAELs (No Observable Adverse Effect Level) were established at 1000 mg/kg/day under the conditions of this study.

Reason / purpose for cross-reference:
reference to other study

Data source

Reference
Reference Type:
study report
Title:
Unnamed
Year:
1996

Materials and methods

Test guideline
Qualifier:
according to guideline
Guideline:
OECD Guideline 414 (Prenatal Developmental Toxicity Study)
Deviations:
yes
Remarks:
females were dosed from Gestation Day (GD) 6 instead of GD 5; Administration volume 5 mL/kg (instead of 4mL/kg max).
Principles of method if other than guideline:
Guideline study
GLP compliance:
not specified
Limit test:
no

Test material

Constituent 1
Chemical structure
Reference substance name:
Hydrocarbons, C16-C20, n-alkanes, isoalkanes, cyclics, <2% aromatics
EC Number:
919-029-3
Molecular formula:
Combination of mainly CnH2n+2 and CnH2n structures, comprised mainly within a carbon number range from C16 to C20
IUPAC Name:
Hydrocarbons, C16-C20, n-alkanes, isoalkanes, cyclics, <2% aromatics
Constituent 2
Reference substance name:
Exxsol D130
IUPAC Name:
Exxsol D130
Constituent 3
Reference substance name:
MRD-94-976
IUPAC Name:
MRD-94-976
Details on test material:
- Name of test material (as cited in study report): Exxsol D130
- Substance type: Hydrocarbon fluid
- Physical state: colorless liquid
- Analytical purity: considered as "pure" material
- Lot/batch No.: 112094
- Expiration date of the lot/batch: March 2000
- Storage condition of test material: Room temperature

Test animals

Species:
rat
Strain:
Crj: CD(SD)
Details on test animals or test system and environmental conditions:
TEST ANIMALS
- Source: Charles River Laboratories, Kingston Facility, New York.
- Age at study initiation: females were approximately 10 weeks at GD 0
- Weight at study initiation: 216 to 295 g at GD 0
- Housing: Single housed during the study period, except during mating
- Diet: Certified Rodent Diet (5002 meal), ad libitum
- Water: ad libitum (Elizabethtown Water company)
- Acclimation period: 14 days


ENVIRONMENTAL CONDITIONS
- Temperature (°C): 20 - 24.4°C
- Humidity (%): 40 - 70%
- Air changes (per hr): Not mentioned
- Photoperiod: 12 hrs dark / 12 hrs light


IN-LIFE DATES: From: To:

Administration / exposure

Route of administration:
oral: gavage
Vehicle:
corn oil
Details on exposure:
VEHICLE
- Amount of vehicle (if gavage): 5 mL/kg
- Lot/batch no. (if required): OCT1295B
- Supplier: Best Foods, CPC International
Analytical verification of doses or concentrations:
yes
Details on analytical verification of doses or concentrations:
At analytical chemistry analysis, excellent uniformity was observed. The percent relative standard deviation (%RSD) ranged from 1.43% to 2.97%. Stability data indicated that the test material was stable in corn oil at ambient temperature for at least 13 days. Concentration verification analysis indicated that the solution in corn oil was within 12% of the nominal concentrations for Week 1 and Week 3.
Details on mating procedure:

- M/F ratio per cage: 1:1 (male:female) ratio
- Length of cohabitation: one night
- Proof of pregnancy: Mating was confirmed by observation of a copulatory plug (vaginal) and/or by the presence of sperm in a vaginal rinse. The day on which mating was confirmed was the female's Day 0 of gestation (GD 0).
Duration of treatment / exposure:
from Gestation Day (GD) 6 through GD 15
Frequency of treatment:
Once daily
Duration of test:
Inlife test period: May 29, 1995 to June 29 1995.
Doses / concentrations
Remarks:
Doses / Concentrations:
0, 400, 800 and 1000 mg/kg/day
Basis:
other: ingested doses
No. of animals per sex per dose:
25 females/dose
Control animals:
yes, concurrent vehicle
Details on study design:
- Dose selection rationale: Doses were selected based on a rangefinding study with Exxsol D130. Results of this study indicated no overt or consistent signs of toxicity at 1000 mg/kg (the limit dose for developmental studies) (OECD, 1981).
- Rationale for animal assignment (if not random): sequential Physical Identification Number

Examinations

Maternal examinations:
CAGE SIDE OBSERVATIONS: Yes
- Time schedule: at least twice daily during the treatment period, otherwise at least once daily.

DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: prior the selection and daily during gestation

BODY WEIGHT: Yes
- Time schedule for examinations: on GD 0, 6, 9, 12, 15, 18, and 21

POST-MORTEM EXAMINATIONS: Yes
- Sacrifice on gestation day 21
- Organs examined: All females assigned to groups were examined by gross necropsies.

OTHER:
Ovaries and uterine content:
The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterus weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of early resorptions: Yes
- Number of late resorptions: Yes
Fetal examinations:
- External examinations: Yes: all per litter
- Soft tissue examinations: Yes: half per litter
- Skeletal examinations: Yes: half per litter
- Head examinations: Yes: [half per litter ]
Statistics:
Statistical treatment of the results was conducted where appropriate. Statistical evaluation of equality of means was done by an appropriate one way analysis of variance and a test for ordered response in the dose groups. First, Bartlett's Test was performed to determine if the dose groups had equal variance . If the variances were equal, the testing was done using parametric methods (ANOVA + Dunnett's), otherwise nonparametric techniques were used (Kruskl-Wallis + Dunn's Summed Rank Test).
Fetal malformation and variation incidence data were analyzed for statistical significance as follows: First, a standard chi-square analysis was performed to determine if the proportions of incidences differ between the groups tested. Next, each treatment group was compared to the control group using a 2 x 2 Fisher Exact Test.
Indices:
Maternal data:
Percentage of pre-implantation loss
Percentage of post-implantation loss

Results and discussion

Results: maternal animals

Maternal developmental toxicity

Details on maternal toxic effects:
Maternal toxic effects:no effects

Details on maternal toxic effects:
No maternal toxic effects.

Effect levels (maternal animals)

Dose descriptor:
NOAEL
Effect level:
> 1 000 mg/kg bw/day (nominal)
Basis for effect level:
other: maternal toxicity

Results (fetuses)

Details on embryotoxic / teratogenic effects:
Embryotoxic / teratogenic effects:yes

Details on embryotoxic / teratogenic effects:
There were statistically significant differences in individual skeletal variations, but were limited to an increase in the incidence of rudimentary lumbar ribs in the 400 mg/kg dose group (14.2%) compared with controls (4.2%) on a per fetus basis. This increased incidence was within the historical control range of this laboratory (3.7-28.8), greater than that observed at higher doses, and thus, not considered biologically important.
The statistically significant increases in the total fetuses with skeletal variations in the 400 mg/kg dose groups were directly driven by the increased incidence of rib variations and thus, were similarly considered as biologically unimportant (within HC range).

Effect levels (fetuses)

Dose descriptor:
NOAEL
Effect level:
> 1 000 mg/kg bw/day (nominal)
Based on:
test mat.
Sex:
male/female
Basis for effect level:
other: Developmental Toxicity

Fetal abnormalities

Abnormalities:
no effects observed

Overall developmental toxicity

Developmental effects observed:
no

Any other information on results incl. tables

No remarks

Applicant's summary and conclusion

Conclusions:
In conclusion, overt signs of maternal toxicity were not apparent at any dose tested, as indicated by the absence of adverse clinical or postmortem findings or effects on body weight, food consumption, and/or uterine implantation data. Similarly, there were no treatment-related adverse effects on fetal development or growth observed at any dose level tested. Accordingly, the maternal and developmental NOAELs (No Observable Adverse Effect Level) were established at 1000 mg/kg (the limit dose) under the conditions of this study.
Executive summary:

The test material was administered by oral gavage to three groups of Crl:CDBR female rats at doses of 400, 800, and 1000 mg/kg/day. A fourth group (Group 1) served as a control and received the carrier (corn oil) only. Mated females were dosed once daily from Gestation Day (GD) 6 through GD 15. Dosing volumes were 5 mL/kg for all groups and based on the animals' most recent body weights.

There was no evidence of overt systemic maternal toxicity at any dose level tested. overt signs of maternal toxicity were not apparent at any dose tested, as indicated by the absence of adverse clinical or postmortem findings or effects on body weight, food consumption, and/or uterine implantation data.

Similarly, there were no treatment-related adverse effects on fetal development or growth observed at any dose level tested. There was a statistically significant increase in the incidence of rudimentary ribs in the low dose (400 mg/kg/day) group, but not at the higher doses, compared with controls, which resulted in an increased incidence of total fetuses with skeletal variations in the 400 mg/kg/day group. However, all these incidences were within the historical control range of this laboratory. Therefore, this common finding in fetal rats was not considered biologically important.

Accordingly, the maternal and developmental NOAELs (No Observable Adverse Effect Level) were established at 1000 mg/kg/day under the conditions of this study.